Patents

Intellectual Property

Our Patent Portfolio

Alpha Cognition, Inc. has exclusively licensed numerous patents from Neurodyn Life Sciences, Inc. in the field of neurology. Below is a representation of these patents:

GLN - 1062

 

Country

Patent/Appl. No.

Title

PCT

WO2009127218

DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES

CA

2,721,007

DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES

CN

ZL200880128608.5

DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES

JP

5504253

DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES

US

US 9,763,953

CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT

US

10,265,325

CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT

EP

2 137 192

DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES

PCT

WO2014016430

ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS

AU

2013294917

ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS

JP

6272857

ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS

JP

6574002

ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS

EP

2 877 165

ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS

 

pending in CA, CN, HK, IN, JP, US, EPO

 

WO

WO2009089635

PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE

CN

CN102006882

PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE

IN

280570

PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE

EP

2 249 861

PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE

EP

3 009 143

PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE

 

pending in CA, US

 

WO

WO2012065248

METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY

JP

6312436

METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY